help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 14, 2004
Molecular Endocrinology, doi:10.1210/me.2004-0096
A more recent version of this article appeared on February 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
19/2/421    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, P. M.
Right arrow Articles by Olefsky, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, P. M.
Right arrow Articles by Olefsky, J. M.

Submitted on March 5, 2004
Accepted on October 5, 2004

Mechanism of SHIP mediated inhibition of Insulin and PDGF-stimulated MAP kinase activity in 3T3-L1 adipocytes

Prem M. Sharma*, Hyun-Shik Son, Satoshi Ugi, William Ricketts, and Jerrold M. Olefsky

Department of Medicine, University of California, San Diego, La Jolla, California 92093, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa, California 92626

* To whom correspondence should be addressed. E-mail: psharma{at}ucsd.edu.

The SH2 containing 5' inositolphosphatases (SHIP and SHIP2) dephosphorylate 3'-phosphorylated PtdIns on the 5' position, decreasing intracellular levels of PtdIns 3,4,5-P3. In the current study, we investigated the role of SHIP in insulin and PDGF signaling by expressing wild-type (WT) and catalytically inactive SHIP{Delta}IP in 3T3-L1 adipocytes, utilizing adenoviral infection. Insulin and PDGF both stimulated tyrosine phosphorylation of SHIP-WT and of SHIP{Delta}IP, and tyrosine phosphorylation of SHIP associated proteins increased after ligand stimulation. Tyrosine-phosphorylated PDGFR, IR and IRS-1 all immunoprecipitated with SHIP. Expression of WT and {Delta}IP SHIP did not affect tyrosine phosphorylation of either the insulin or the PDGF receptor, or the expression of IRS-1 and Shc proteins. Both SHIP-WT and SHIP{Delta}IP blocked insulin and PDGF-induced MAPK and MEK phosphorylation as well as, GTP-bound Ras activity, suggesting that the catalytic activity of SHIP is not necessary for these effects. SHIP associated with Shc upon ligand stimulation, indicating that the SHIP-Shc association is phosphorylation dependent. This association was primarily between the SHIP-SH2 domain and the phosphorylated tyrosine residues of Shc, as no association was observed when the 3YF-Shc mutant was co-expressed with SHIP. The Shc•Grb2 association was not compromised by SHIP expression, despite complete inhibition of the Ras/MAPK pathway. Interestingly, SOS protein normally found in Grb2 complexes was markedly reduced in SHIP expressing cells, whereas the displaced SOS was recovered when the post Grb2-IP supernatants were blotted with anti-SOS antibody. Thus, SHIP competes SOS away from Shc-Grb2. In summary, 1) SHIP-WT and SHIP{Delta}IP expression inhibit insulin and PDGF stimulated Ras, MEK and MAPK activities 2) SHIP associates with tyrosine phosphorylated Shc, and the proline rich sequences in SHIP associate with Grb2 and titrate out SOS to form Shc•Grb2•SHIP complexes. 3) Dissociation of SOS from the Shc•Grb2 complex inhibits Ras GTP loading leading to decreased signaling through the MAPK pathway.


Key words: SHIP • MAP kinase • Insulin • PDGF • adipocytes







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society